329 related articles for article (PubMed ID: 23406560)
21. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
22. Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer.
Owen S; Ye L; Sanders AJ; Mason MD; Jiang WG
Anticancer Res; 2013 Jan; 33(1):199-206. PubMed ID: 23267146
[TBL] [Abstract][Full Text] [Related]
23. Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.
Dempster DW; Lambing CL; Kostenuik PJ; Grauer A
Clin Ther; 2012 Mar; 34(3):521-36. PubMed ID: 22440513
[TBL] [Abstract][Full Text] [Related]
24. RANKL and RANK in sex hormone-induced breast cancer and breast cancer metastasis.
Schramek D; Sigl V; Penninger JM
Trends Endocrinol Metab; 2011 May; 22(5):188-94. PubMed ID: 21470874
[TBL] [Abstract][Full Text] [Related]
25. The inhibition of RANKL/RANK signaling by osteoprotegerin suppresses bone invasion by oral squamous cell carcinoma cells.
Shin M; Matsuo K; Tada T; Fukushima H; Furuta H; Ozeki S; Kadowaki T; Yamamoto K; Okamoto M; Jimi E
Carcinogenesis; 2011 Nov; 32(11):1634-40. PubMed ID: 21890459
[TBL] [Abstract][Full Text] [Related]
26. Role of the RANK/RANKL pathway in breast cancer.
Kiesel L; Kohl A
Maturitas; 2016 Apr; 86():10-6. PubMed ID: 26921922
[TBL] [Abstract][Full Text] [Related]
27. [Clinical perspectives of the study of RANK/RANKL/OPG system components in primary and metastatic bone tumor].
Kushlinskiĭ NE; Timofeev IuS; Gershteĭn ES; Solov'ev IuN
Vopr Onkol; 2014; 60(4):413-21. PubMed ID: 25552059
[TBL] [Abstract][Full Text] [Related]
28. The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction.
Goessl C; Katz L; Dougall WC; Kostenuik PJ; Zoog HB; Braun A; Dansey R; Wagman RB
Ann N Y Acad Sci; 2012 Aug; 1263():29-40. PubMed ID: 22831177
[TBL] [Abstract][Full Text] [Related]
29. Bone metastasis: can osteoclasts be excluded?
Martin TJ; Mundy GR
Nature; 2007 Feb; 445(7130):E19; discussion E19-20. PubMed ID: 17314931
[TBL] [Abstract][Full Text] [Related]
30. [Anti-RANKL monoclonal antibody Denosumab (AMG162)].
Sugimoto T
Clin Calcium; 2011 Jan; 21(1):46-51. PubMed ID: 21187593
[TBL] [Abstract][Full Text] [Related]
31. [The clinical merit of anti-RANKL antibody denosumab in prostate cancer].
Akaza H; Tsukamoto T; Suzuki K; Namiki M; Ozono S; Naitodept S
Gan To Kagaku Ryoho; 2012 Feb; 39(2):207-12. PubMed ID: 22333629
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications.
De Castro J; García R; Garrido P; Isla D; Massuti B; Blanca B; Vázquez J
Clin Lung Cancer; 2015 Nov; 16(6):431-46. PubMed ID: 26264596
[TBL] [Abstract][Full Text] [Related]
33. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone.
Branstetter DG; Nelson SD; Manivel JC; Blay JY; Chawla S; Thomas DM; Jun S; Jacobs I
Clin Cancer Res; 2012 Aug; 18(16):4415-24. PubMed ID: 22711702
[TBL] [Abstract][Full Text] [Related]
34. RANKL signaling in bone physiology and cancer.
Dougall WC
Curr Opin Support Palliat Care; 2007 Dec; 1(4):317-22. PubMed ID: 18685382
[TBL] [Abstract][Full Text] [Related]
35. [Treatment of bone metastasis with anti-RANKL antibody].
Chayahara N; Minami H
Clin Calcium; 2011 Aug; 21(8):1217-22. PubMed ID: 21814028
[TBL] [Abstract][Full Text] [Related]
36. Updates on the role of receptor activator of nuclear factor κB/receptor activator of nuclear factor κB ligand/osteoprotegerin pathway in breast cancer risk and treatment.
Bayer CM; Beckmann MW; Fasching PA
Curr Opin Obstet Gynecol; 2017 Feb; 29(1):4-11. PubMed ID: 28002265
[TBL] [Abstract][Full Text] [Related]
37. Inhibitory effect of metformin on bone metastasis of cancer via OPG/RANKL/RANK system.
Wang J; Chen TY; Qin S; Duan Y; Wang G
Med Hypotheses; 2013 Nov; 81(5):805-6. PubMed ID: 24074896
[TBL] [Abstract][Full Text] [Related]
38. Targeting receptor-activator of nuclear kappaB ligand in aneurysmal bone cysts: verification of target and therapeutic response.
Pelle DW; Ringler JW; Peacock JD; Kampfschulte K; Scholten DJ; Davis MM; Mitchell DS; Steensma MR
Transl Res; 2014 Aug; 164(2):139-48. PubMed ID: 24726460
[TBL] [Abstract][Full Text] [Related]
39. The RANKL/RANK system as a therapeutic target for bone invasion by oral squamous cell carcinoma (Review).
Jimi E; Shin M; Furuta H; Tada Y; Kusukawa J
Int J Oncol; 2013 Mar; 42(3):803-9. PubMed ID: 23354319
[TBL] [Abstract][Full Text] [Related]
40. [Bone metastasis and RANKL].
Nakashima T
Clin Calcium; 2014 Aug; 24(8):1201-8. PubMed ID: 25065872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]